Investigation of asymptomatic carotid stenosis treatment is hindered by the lack of a contemporary population-based disease cohort. We describe the use of natural language processing (NLP) to identify stenosis in patients undergoing carotid imaging. Adult patients with carotid imaging between 2008 and 2012 in a large integrated health care system were identified and followed through 2017. An NLP process was developed to characterize carotid stenosis according to the Society of Radiologists in Ultrasound (for ultrasounds) and North American Symptomatic Carotid Endarterectomy Trial (NASCET) (for axial imaging) guidelines. The resulting algorithm assessed text descriptors to categorize normal/non-hemodynamically significant stenosis, moderate or severe stenosis as well as occlusion in both carotid ultrasound (US) and axial imaging (computed tomography and magnetic resonance angiography [CTA/MRA]). For US reports, internal carotid artery systolic and diastolic velocities and velocity ratios were assessed and rch and holds promise for similar reporting in other vascular diseases. Examine the endovascular community response to data demonstrating increased mortality in paclitaxel devices for the treatment of peripheral arterial disease in femoropopliteal lesions. A retrospective observational study using the Vascular Quality Initiative Peripheral Vascular Intervention registry dataset was performed examining paclitaxel device use for peripheral arterial disease in femoropopliteal arteries treated from 2017-2019. A total of 41707 patients and 52208 procedures were analyzed during the study period. Post-hoc analysis was performed to examine use during selected time periods in 2019. Total femoropopliteal procedures in 2017, 2018, and 2019 were 17458, 21140, and 21322, respectively. Paclitaxel devices were used for 8852 arteries in 2017, 10691 in 2018, and 6732 in 2019, which was significantly reduced, when comparing 2019 volumes to 2017 or 2018 (p < .0001) and 2019 versus 2018 + 2017 volumes (p < .0001). Post-hoc analysis of selected times in 2019 demonstrated variable use throughout 2019. Following publication of data with concerns of mortality associated with paclitaxel device use in 2018, a rapid reduction in overall paclitaxel device use was observed in 2019.Following publication of data with concerns of mortality associated with paclitaxel device use in 2018, a rapid reduction in overall paclitaxel device use was observed in 2019. Statin use is associated with higher long-term survival after abdominal aortic aneurysm repair. cGAS inhibitor However, the association between statin use and survival after thoracic endovascular aortic repair (TEVAR) has not been established. We performed a review of prospectively collected data of all patients who had undergone TEVAR in the Vascular Quality Initiative between 2014 and 2020. We excluded patients aged<18years, those who had presented with trauma, and those who had received custom-manufactured or physician-modified devices. We evaluated the association between preoperative statin therapy and in-hospital mortality and complications and 5-year mortality. We also analyzed the trend of preoperative statin use in elective cases for the previous 7years. To account for nonrandom assignment to treatment, we used propensity score matching of patient characteristics, comorbidities, pathology, and urgency for preoperative statin use. We used logistic regression and Cox regression for the short-term and 5-year ouerapy unless contraindications for the drug are present. For patients undergoing elective TEVAR, the statin prescription percentage should be considered a quality metric, and further implementation research should occur to improve preoperative statin use. Mechanisms of procedural stroke after carotid endarterectomy (CEA) or stenting (CAS) are surprisingly underresearched. However, understanding the underlying mechanism could (1) assist in balancing the choice for revascularization versus conservative therapy; (2) assist in choosing either open or endo techniques; and (3) assist in taking appropriate periprocedural measures to further reduce procedural stroke rate. The purpose of this study was to overview mechanisms of procedural stroke after carotid revascularization and establish reporting standards to facilitate more granular investigation and individual patient data meta-analysis in the future. A systematic review was conducted according to the Preferred Reporting Items for Systematic reviews and Meta-analysis (PRISMA) statement. The limited evidence in literature was heterogeneous and of low quality and hence no formal data meta-analysis could be performed. Procedural stroke was classified as haemorrhagic or ischemic; the latter was subclassified as propose a standardized form enclosing reporting standards for procedural stroke with a systematic approach to inference of the most likely aetiology, for prospective use in registries and RCTs on carotid revascularization.Although procedural stroke incidence and aetiology may have changed over the last decades due to technical improvements and improvement in perioperative monitoring and quality control, the lack of literature data limits further statements. To simplify and enhance future reporting, procedural stroke analysis and classification should be documented pre-emptively in research settings. We propose a standardized form enclosing reporting standards for procedural stroke with a systematic approach to inference of the most likely aetiology, for prospective use in registries and RCTs on carotid revascularization. Although no drug-eluting stent (DES) has been approved by the Food and Drug Administration to treat infrapopliteal arterial disease, several industry-sponsored trials have reported the outcomes with the use of paclitaxel or sirolimus DESs. To the best of our knowledge, only one study to date has reported on the use of everolimus DESs for infrapopliteal arterial disease. In the present study, we analyzed the clinical outcomes with everolimus DESs in our real-world, single-center experience. A total of 107 limbs with critical limb threatening ischemia (98 patients; 118 lesions) treated with DESs (Xience; Abbott Vascular, Santa Clara, Calif) were analyzed. The postoperative early outcomes, major adverse limb events (above the ankle limb amputation or major intervention at 1year), and major adverse events (death, amputation, target lesion thrombosis or reintervention) were analyzed. Kaplan-Meier analysis was used to estimate the primary patency rates (using duplex ultrasound), amputation-free rates, and amputation-free survival rates.